-Moment-tomoment adjustment of cerebral blood flow (CBF) to neuronal activity via neurovascular coupling is essential for the maintenance of normal neuronal function. Increased oxidative stress that occurs with aging was shown to impair neurovascular coupling, which likely contributes to a significant age-related decline in higher cortical function, increasing the risk for vascular cognitive impairment. Resveratrol is a polyphenolic compound that exerts significant antiaging protective effects in large vessels, but its effects on the cerebromicrovasculature remain poorly defined. The present study was undertaken to investigate the capacity of resveratrol to improve neurovascular coupling in aging. In aged (24-mo-old) C57BL/6 mice N -nitro-L-arginine methyl ester-sensitive, nitric oxide-mediated CBF responses to whisker stimulation and to the endothelium-dependent dilator acethylcholine (ACh) were impaired compared with those in young (3-mo-old) mice. Treatment of aged mice with resveratrol rescued neurovascular coupling and ACh-induced responses, which was associated with downregulation of cortical expression of NADPH oxidase and decreased levels of biomarkers of oxidative/nitrative stress (3-nitrotyrosine, 8-isoprostanes). Resveratrol also attenuated age-related increases in reactive oxygen species (ROS) production in cultured cerebromicrovascular endothelial cells (DCF fluorescence, flow cytometry).
In conclusion, treatment with resveratrol rescues cortical neurovascular coupling responses to increased neuronal activity in aged mice, likely by restoring cerebromicrovascular endothelial function via downregulation of NADPH oxidase-derived ROS production. Beneficial cerebromicrovascular effects of resveratrol may contribute to its protective effects on cognitive function in aging.
senescence; oxidative stress; ROS; reactive hyperemia; vascular cognitive impairment; microvascular dysfunction NORMAL BRAIN FUNCTION IS CRITICALLY dependent on a continuous, tightly controlled supply of oxygen and glucose through cerebral blood flow (CBF). Although energetic demands of neurons are very high, the brain has very little reserve capacity. During periods of intense neuronal activity, there is a requirement for rapid increases in oxygen and glucose delivery. This is ensured by neurovascular coupling, a vital mechanism of regulation of CBF that maintains optimal microenvironment of cerebral tissue by adjusting local blood flow to local neuronal activity (3) . Since higher processes in the brain occur almost instantly, moment-to-moment adjustment of CBF via neurovascular coupling is essential for the maintenance of normal neuronal function. There is strong evidence that neurovascular coupling is impaired in the elderly (12, 40, 43, 53) , which likely contributes to a significant age-related decline in higher cortical function, including cognition (38) and gait coordination (39) . Thus therapeutic interventions that improve neurovascular coupling in elderly patients have the potential to improve a range of age-related neurological deficits.
Neurovascular coupling and cerebral functional hyperemia depend on a coordinated interaction of activated neurons, astrocytes, and vascular endothelial and smooth muscle cells. Transduction of signals from neurons and astrocytes initiate regional vasodilation in the cerebral microcirculation, which involve production and release of nitric oxide (NO) by microvascular endothelial cells (14, 41, 55) . Previous studies demonstrate that aging is associated with an increased production of NADPH oxidase-derived reactive oxygen species (ROS) in the cerebral microvasculature, which contribute to compromised neurovascular coupling in aged mice (28) , likely by decreasing bioavailability of NO and promoting endothelial dysfunction (13, 28, 43, 53) . On the basis of the aforementioned findings it is logical to hypothesize that pharmacological treat-ments that improve endothelial function will have the capacity to improve neurovascular coupling in aged individuals.
Recent studies provide strong evidence that treatment of laboratory rodents with resveratrol (3,4=,5-trihydroxystilbene), a plant-derived polyphenolic compound, exerts significant endothelial protective effects in the aorta and vessels from the peripheral circulation both during aging and in pathophysiological conditions that are associated with accelerated vascular aging (31, 46, 50, 51, 57) . Importantly, resveratrol was shown to increase bioavailability of endothelium-derived NO and inhibit NADPH oxidases in large vessels (31, 33, 54, 56, 57) . Although resveratrol has been shown to exert beneficial effects on the age-dependent decline in cognitive function (26, 58) , its potential protective effect on the aged cerebral microvasculature has not been investigated.
The present study was designed to test the hypothesis that resveratrol treatment, similar to its documented vasoprotective effects in the aorta, can restore cerebromicrovascular endothelial function and thus improve neurovascular coupling in aged mice. To achieve this goal, aged mice were treated with resveratrol followed by tests for neurovascular coupling and cerebromicrovascular endothelial function. Markers of oxidative stress and expression of NADPH oxidase in the cerebral cortex were also assessed. To substantiate the in vivo findings, the effects of resveratrol on ROS production and expression of NADPH oxidase in activated cultured astrocytes and in cerebromicrovascular endothelial cells derived from aged animals were obtained in vitro.
MATERIALS AND METHODS
Animals, resveratrol treatment. Young (3 mo, n ϭ 30) and aged (24 mo, n ϭ 30) male C57BL/6 mice were purchased from the aging colony maintained by the National Institute on Aging at Charles River Laboratories (Wilmington, MA). Animals were housed under specific pathogen-free barrier conditions in the Rodent Barrier Facility at University of Oklahoma Health Sciences Center under a controlled photoperiod (12-h light; 12-h dark) with unlimited access to water. Mice in each age cohort were assigned to two groups (n ϭ 15 each group) and were fed a standard AIN-93G diet (ad libitum) or a standard diet plus resveratrol (200 mg·kg Ϫ1 ·day Ϫ1 , for 10 days) following previously described protocols (31, 46, 50) . All procedures were approved by the Institutional Animal Use and Care Committees of the University of Oklahoma Health Sciences Center.
Measurement of cerebral blood flow responses to whisker stimulation and pharmacological studies. At the end of the treatment period, mice in each group were anesthetized with ␣-chloralose (50 mg/kg ip) and urethane (750 mg/kg ip), endotracheally intubated, and ventilated (MousVent G500; Kent Scientific, Torrington, CT). Rectal temperature was maintained at 37°C using a thermostatic heating pad (Kent Scientific).
End-tidal CO2 (including dead space) was maintained between 3.2 and 3.7% to keep blood gas values within the physiological range (PaCO2: 37.3 Ϯ 1.9 mmHg; PaO2: 108 Ϯ 3 mmHg). Mice were immobilized and placed on a stereotaxic frame (Leica Microsystems, Buffalo Grove, IL), the scalp and periosteum were pulled aside and the skull was removed over the barrel cortex, and the dura was gently removed. The cranial window was superfused with artificial cerebrospinal fluid (composition: 119 mM NaCl, 26.2 mM NaHCO3, 2.5 mM KCl, 1 mM NaH2PO4, 1.3 mM MgCl2, 10 mM glucose, and 2.5 mM CaCl2, pH 7.3, 37°C). The right femoral artery was cannulated for arterial blood pressure measurement (Living Systems Instrumentations, Burlington, VT). The blood pressure was within the physiological range throughout the experiments (in mmHg; young: 100 Ϯ 2; aged: 103 Ϯ 2.3; and aged ϩ resveratrol: 108 Ϯ 1.5). A laser Doppler probe (Transonic Systems, Ithaca, NY) was placed above the barrel cortex (1-1.5 mm posterior and 3-3.5 mm lateral to bregma), and to achieve the highest CBF response the right whiskers were stimulated for 1 min at 10 Hz from side to side. Changes in CBF (n ϭ 7 in each group) were assessed above the left barrel cortex in three trials, separated by 5-to 10-min intervals. CBF responses to whisker stimulation were repeated in the presence of the NADPH oxidase inhibitor apocynin (3 ϫ 10 Ϫ4 mol/l) administered topically to the brain surface for 30 min (8, 57) . In a separate series of experiments (n ϭ 8 in each group), CBF responses to whisker stimulation and to topical administration of acetylcholine (ACh; 10 Ϫ5 mol/l) and adenosine (5 ϫ 10 Ϫ5 mol/l) were obtained in the presence and absence of the NO synthase inhibitor N -nitro-L-arginine methyl ester (L-NAME; 10 Ϫ4 mol/l, 20 min) and then in the presence of the muscarinic ACh receptor antagonist atropine (10 Ϫ5 mol/l). Changes in CBF were expressed as percent (%) increase from the baseline value (16) . The experimenter was blinded to the treatment of the animals. At the end of the experiments, the animals were transcardially perfused and decapitated. The brains were immediately removed, and pieces of the somatosensory and motor cortex were isolated and frozen for subsequent analysis.
Assessment of the effect of in vivo resveratrol treatment on markers of oxidative stress. To characterize the effect of resveratrol treatment on cellular redox homeostasis in aging, 3-nitrotyrosine (a marker for peroxynitrite action) was assessed in homogenates of cortical samples using 
R. norvegicus CTTCTCTGTGTTCTACTATG TATCAAGTTCAGCAATGG
OxiSelect Protein Nitrotyrosine ELISA Kits (Cell Biolabs), according to the manufacturer's guidelines, as previously described (44) .
As an additional marker of oxidative stress, the total tissue 8-isoprostane content was measured in cerebral cortical samples using the 8-isoprostane EIA kit (Cayman Chemicals) according to the manufacturer's guidelines, as previously described (32) . In brief, samples were homogenized in 100 mmol/l potassium phosphate buffer (pH 7.4) containing 1 mmol/l EDTA and 0.005% BHT using a Precellys 24 tissue homogenizer with CK28 ceramic beads at 5,500 rpm for two cycles of 20 s. Samples were centrifuged, and the supernatant was collected. Fifty microliters of each sample were reserved for protein determination. An equal volume of 15% KOH was added to the remaining sample in each tube, and samples were incubated for 1 h at 40°C to hydrolyze 8-isoprostane esterified to phospholipids. Samples were neutralized by the addition of 1 mol/l HCl. Samples were then purified using 8-isoprostane affinity columns according to the manufacturer's guidelines, dried under nitrogen, and resuspended with EIA buffer before analysis. A standard curve was established by serial dilution of 8-isoprostane between 0.8 and 500 pg/ml using EIA Buffer as the matrix. The concentration of each sample was calculated from a logistic four-parameter fit of the standard concentrations vs. percent bound/maximum bound (%B/B 0). Protein concentrations were determined using a Bradford assay.
Quantitative real-time RT-PCR. A quantitative real-time RT-PCR
technique was used to analyze mRNA expression for following genes in cortical samples of mice from each experimental group: Nox1, Nox2, Nox4, and Ncf1 (p47phox) using a Strategen MX3000 platform, as previously reported (4) ( Table 1 ). In brief, total RNA was isolated with a Mini RNA Isolation Kit (Zymo Research, Orange, CA) and was reverse transcribed using Superscript III RT (Invitrogen) as described previously (4) . Amplification efficiencies were determined using a dilution series of a standard vascular sample. Quantification was performed using the efficiency-corrected ⌬⌬Cq method. The relative quantities of the reference genes Hprt, Ywhaz, B2m, and Actb were determined, and a normalization factor was calculated based on the geometric mean for internal normalization. Fidelity of the PCR reaction was determined by melting temperature analysis and visualization of the product on a 2% agarose gel.
Assessment of the effect of in vitro resveratrol treatment on ROS production in cultured cerebromicrovascular endothelial cells and astrocytes. To confirm the direct antioxidative effect of resveratrol in vitro in cells involved in neurovascular coupling, we assessed the effect of resveratrol on cellular ROS production in cultured primary cerebromicrovascular endothelial cells (CMVECs) and astrocytes. The establishment and characterization of the cell strains used have been recently reported (45, 49) .
In brief, to establish primary cultures of CMVECs, the brains of male 3-and 24-mo-old F344xBN rats (obtained from the National Institute on Aging) were removed aseptically, rinsed in ice cold PBS and minced into Ϸ1-mm squares. The tissue was washed twice in ice cold 1ϫ PBS by low-speed centrifugation (50 g, 2-3 min). The diced tissue was digested in a solution of collagenase (800 U/g tissue), hyaluronidase (2.5 U/g tissue), and elastase (3 U/g tissue) in 1ml PBS/100 mg tissue for 45 min at 37°C in a rotating humid incubator. The digested tissue was passed through a 100-um cell strainer. The single cell lysate was centrifuged for 2 min at 70 g. After the supernatant was removed, the pellet was washed twice in cold PBS supplemented with 2.5% fetal calf serum (FCS) and the suspension was centrifuged at 300 g for 5 min at 4C. To create an endothelial cell enriched fraction, the cell suspension was centrifuged using an OptiPrep gradient solution (Axi-Shield, PoC). Briefly, the cell pellet was resuspended in HBSS and mixed with 40% iodixanol thoroughly [final concentration: 17% (wt/vol) iodixanol solution; ϭ 1.096 g/ml]. Two milliliters of HBSS were layered on top and centrifuged at 400 g for 15 min at 20°C. Endothelial cells, which banded at the interface between HBSS and the 17% iodixanol layer, were collected. The endothelial cell enriched fraction was incubated for 30 min at 4°C in the dark with anti-CD31/PE (BD Biosciences, San Jose, CA) and anti-MCAM/FITC (BD Biosciences). After the cells were washed twice with MACS Buffer (Milltenyi Biotech, Cambridge, MA), anti-FITC magnetic beads labeled with anti-PE magnetic bead-labeled secondary antibodies were used for 15 min at room temperature. Endothelial cells were collected by magnetic separation using the MACS LD magnetic separation columns according to the manufacturer's guidelines (Milltenyi Biotech). The endothelial fraction was cultured on fibronectin-coated plates in endothelial growth medium (Cell Application, San Diego, CA) for 10 days. Endothelial cells were phenotypically characterized by flow cytometry (GUAVA 8HT; Merck Millipore, Billerica, MA). Briefly, antibodies against five different endothelial-specific markers were used (anti-CD31-PE, antierythropoietin receptor-APC, anti-VEGF R2-PerCP, anti-ICAM-fluorescein, and anti-CD146-PE) and isotype-specific antibody labeled fractions served as negative controls. Flow cytometric analysis showed that after the third cycle of immunomagnetic selection there were virtually no CD31, CD146, EpoR, and VEGFR2 cells in the resultant cell populations. All antibodies were purchased from R&D Systems (Minneapolis, MN). To assess the direct effects of resveratrol on endothelial ROS production, primary CMVECs derived from young and aged rats were treated with resveratrol in vitro (10 mol/l, for 24 h). Primary cultures of astrocytes were derived from postnatal days 2-5 F344 rat pups following previously described methods (2) . Briefly, cortical tissue was enzymatically and mechanically digested, resuspended in growth media [DMEM containing 2% NuSerum, 10% fetal bovine serum, penicillin (10 U/ml), streptomycin (10 g/ml), and L-glutamine (29.2 g/ml)] at a density of 2.5 million cells/ml, and seeded on 50 g/ml poly-D-lysine-coated T75-flasks. Fresh growth media was supplemented every 3-4 days. Oligodendrocytes and microglia were removed via immunopanning on day 10. Astrocytes were then trypsinized and passaged into a 96-well plate and grown in fresh growth media. Resulting cultures are ϳ93% GFAP-positive astrocytes (2) . To assess the direct effects of resveratrol on ROS production by astrocytes, primary astrocytes in culture were incubated for 24 h with resveratrol (10 mol/l) and then activated by treatment with 10 ng/ml TNF-␣, 10 ng/ml IL-1␤, and 10 ng/ml IL-6 (for 4 h).
After the experimental period peroxide production in cultured CMVECs and astrocytes was assessed using the cell-permeant oxidative fluorescent indicator dye CM-H 2DCFDA [5 (and 6)-chloromethyl-2=,7=-dichlorodihydrofluorescein diacetate-acetyl ester; Life Technology, Carlsbad, CA] as previously reported (7, 48) . In brief, following the treatment period cells were incubated with CM-H 2DCFDA (10 M, at 37°C, for 30 min). CM-H2DCFDA fluorescence was assessed by flow cytometry as previously reported (7, 48) using the Guava easyCyte 8HT flow-cytometer (Millipore).
Statistical analysis. Data were analyzed by two-way ANOVA followed by Tukey's post hoc test. P Ͻ 0.05 was considered statistically significant. Data are expressed as mean Ϯ SE.
RESULTS

Treatment with resveratrol rescues NO mediation of neurovascular coupling in aged mice.
Changes in CBF in the whisker barrel cortex in response to contralateral whisker stimulation was significantly decreased in aged mice compared with young animals indicating impaired neurovascular coupling in aging (representative tracings are shown in Fig. 1A , summary data are shown in Fig. 1B) (28) . We found that 10 days of treatment with resveratrol significantly increased CBF responses induced by contralateral whisker stimulation in aged mice, restoring neurovascular coupling to levels observed in young mice (Fig. 1B) . Resveratrol treatment did not affect neurovascular coupling in young animals (Fig. 1B) . Resveratrol treatment did not affect baseline CBF neither in young mice nor in aged mice (Fig. 1C) .
In young animals administration of the NO synthase inhibitor L-NAME significantly decreased CBF responses in the barrel cortex elicited by contralateral whisker stimulation, eliminating the differences between the age groups ( Fig. 2A) . In untreated aged animals administration of L-NAME was without effect (Fig. 2A) . In contrast in resveratrol-treated aged mice L-NAME significantly decreased CBF responses elicited by whisker stimulation (Fig. 2A) , suggesting that resveratrol treatment restored the NO mediation of neurovascular coupling in aged animals (Fig. 2B) .
Treatment with resveratrol reverses aging-induced impairment of ACh-induced, NO-mediated endothelial responses.
Topical application of the endothelium-dependent vasodilator agent ACh (10 Ϫ5 mol/l) resulted in a significant increase in CBF in the barrel cortex of young mice (Fig. 3A) . ACh-induced increases in CBF were significantly attenuated (ϳ50%) in aging mice (Fig. 3A) . Treatment of aged mice with resveratrol significantly improved ACh-induced CBF responses, restoring responses to the level observed in young mice (Fig. 3A) . Administration of ACh was reported to affect CBF through stimulation of endothelial NO production and by activation of neuronal muscarinic ACh receptors (14, 18, 55) . To assess the endothelium-dependent component of ACh-induced responses, L-NAME was applied. L-NAME significantly inhibited AChinduced CBF responses both in young animals and resveratroltreated aged mice, whereas it did not exert a significant effect in untreated aged mice (Fig. 3, A and B) . After administration of L-NAME, ACh-induced CBF responses did not differ among young, aged and resveratrol-treated aged mice (Fig. 3, A and B) . derived from young and aged F344xBN rats. Shown is the effect of resveratrol treatment (10 mol/l, for 24 h) on ROS production by aged CMVECs. Appropriate control (unstained cells) is also shown. B: resveratrol (10 mol/l, for 24 h) attenuates increased ROS production in aged CMVECs. Data are means Ϯ SE (n ϭ 8 in each group). *P Ͻ 0.05 vs. young control;
# P Ͻ 0.05 vs. aged control. C: resveratrol (10 mol/l, for 24 h) attenuates increased ROS production in activated astrocytes. Primary astrocytes in culture were stimulated by treatment with 10 ng/ml TNF-␣, 10 ng/ml IL-1␤, and 10 ng/ml IL-6 (for 4 h) with and without resveratrol pretreatment (10 mol/l, for 24 h). Cellular ROS production was measured using the DCF fluorescence method by flow cytometry. Data are means Ϯ SE (n ϭ 8 in each group). *P Ͻ 0.05 vs. control;
# P Ͻ 0.05 vs. stimulated cells (no resveratrol).
Coadministration of L-NAME and the muscarinic ACh receptor antagonist atropine (5 ϫ 10 Ϫ5 mol/l) abolished the remaining ACh-induced CBF response in each experimental group (data not shown). CBF responses elicited by administration of adenosine (which predominantly acts on vascular smooth muscle cells) did not differ significantly among the experimental groups and were not affected significantly by administration of L-NAME or L-NAME plus atropine (Fig. 3, A-C) .
NADPH oxidase inhibitor apocynin reverses neurovascular dysfunction in aged mice. The CBF response in aged animals was significantly increased by treatment with the NADPH oxidase inhibitor apocynin (Fig. 4A) supporting the concept that increased production of ROS by NADPH oxidases play a central role in aging-induced cerebromicrovascular dysfunction.
Treatment with resveratrol attenuates aging-induced oxidative stress. 3-nitrotyrosine content in the cerebral cortex was significantly elevated in aged mice (Fig. 4B ) consistent with increased oxidative/nitrosative stress in the aged brain (6, 23) . Resveratrol treatment significantly reduced 3-nitrotyrosine content in the cortex of aged mice (Fig. 4B ), as well as the level of 8-isoprostane. These results support the concept that antioxidative effects of resveratrol play a central role in its microvascular protective effects in aging.
In vitro treatment with resveratrol attenuates oxidative stress in aged microvascular endothelial cells and activated astrocytes. To substantiate the antioxidative effects of resveratrol in vitro, we assessed the effects of resveratrol on cellular ROS production in cultured CMVECs derived from aged animals using the DCF fluorescence method. We found that ROS production in CMVECs derived from aged animals was significantly increased compared with that in CMVECs derived from young animals (Fig. 5, A and B) . Resveratrol treatment significantly decreased ROS production in aged CMVECs, eliminating the difference between the two age groups (Fig.  5B) . Aging is also associated with activation of astrocytes (36) , and increased ROS production in activated astrocytes (37) may also affect the efficiency of neurovascular coupling. To determine whether resveratrol can also affect astrocytic ROS production, activated cultured astrocytes were treated with resveratrol. We found that resveratrol treatment significantly decreased ROS production in cytokine-stimulated astrocytes (Fig. 5C) .
Treatment with resveratrol attenuates expression of NADPH oxidases in the aged mouse brain. NADPH oxidases are important sources of ROS in the cerebral vasculature, whose increased expression and activity contribute to impaired neurovascular coupling (Fig. 4A) (28) . We found that in the cortex of aged mice mRNA expression of the NADPH oxidase subunits Nox1, Nox2, and Nox4 were upregulated compared with young mice (Fig. 6, A-C) , extending recent findings (28) . Treatment of aged mice with resveratrol resulted in significant downregulation of these NADPH oxidase subunits, normalizing their expression to control levels (Fig. 6, A-C) . The expression of Ncf1 also tended to increase in the aged brain and there was also a tendency for downregulation by resveratrol treatment, although these changes did not reach statistical significance (Fig. 6D) .
In vitro treatment with resveratrol downregulates expression of NADPH oxidases in aged microvascular endothelial cells.
To extend our in vivo findings, a parallel in vitro analysis of the effect of resveratrol on expression of NADPH oxidases in aged CMVECs was undertaken. We found that in aged CMVECs mRNA expression of the NADPH oxidase subunits Nox2 and Nox4 were upregulated compared with young CMVECs (Fig. 7) . Resveratrol treatment resulted in significant downregulation of these NADPH oxidase subunits in aged CMVECs (Fig. 7) .
DISCUSSION
This is the first study to demonstrate positive effects of resveratrol on neurovascular coupling responses in a mouse model of aging that recapitulates cerebromicrovascular alterations and deficits of higher cortical function present in elderly humans.
We demonstrate that aging leads to profound neurovascular dysregulation (28) , characterized by impaired CBF responses induced by neuronal activity (Fig. 1) . Age-related impairment of neurovascular coupling manifests in elderly patients (40, 43, 53) and has been causally linked to the decline in higher cortical functions including cognition (38, 39) . Here, we demonstrate for the first time that aging-induced decrease in neurovascular coupling is restored by treatment with resveratrol (Fig. 1B) . Restoration of a key homeostatic mechanism matching energy supply with the needs of active neuronal tissue likely has beneficial effect on brain function in aging. Thus it is logical to hypothesize that the significant improvement of neurovascular coupling contributes to the documented beneficial effect of resveratrol treatment on cognitive function that has been reported in aged rodents (19, 26, 58) .
Our findings have important clinical relevance. In humans resveratrol is well tolerated with no reports of significant toxicity (5) . Although the bioavalibility of resveratrol in parenchymal tissues is relatively low, the vascular endothelium, which is in direct contact with blood, is considered an ideal target for circulating resveratrol and its active metabolites (5) . There is initial evidence that in humans short-term resveratrol administration results in dose-dependent increases in cerebral blood flow during task performance (17) . In addition, epidemiological studies suggest that Mediterranean diets that are rich in resveratrol are associated with significantly reduced risk of age-related cognitive decline in humans (52) . Recent evidence suggests that regular consumption of the cocoa-derived dietary polyphenol epicathecin (38) may also improve cognitive function in older individuals; thus further studies addressing whether in geriatric patients short-term and/or long-term dietary intake of resveratrol as a supplement can improve neurovascular coupling and reduce the incidence or severity of age-related cognitive decline appear critical (25) .
There is growing experimental evidence that endothelial NO production has an important role in neurovascular coupling (14, 20, 41) . This concept is supported by our observation that inhibition of NO synthesis dramatically reduces neurovascular coupling in young mice ( Fig. 2A) . The findings that in aged mice inhibition of endothelial NO synthesis did not decrease the CBF responses elicited by neuronal activity ( Fig. 2A) suggest that cerebromicrovascular endothelial dysfunction underlies age-related dysregulation of neurovascular coupling (Fig. 2B) (28) . The dilator capacity of smooth muscle cells in the aged cerebral vasculature is not impaired, as shown by the intact responses to adenosine (Fig. 3C ) and the NO donor S-nitroso-N-acetyl-penicillamine (28) . Resveratrol treatment restored NO mediation of neurovascular coupling in aged animals ( Fig. 2A) supporting the concept that endothelial protective effects play a key role in preservation of neuronal function in aging. Additional evidence in support of this concept comes from the observations that resveratrol treatment rescued ACh-induced, endothelial NO-mediated cerebromicrovascular dilation in aged mice (Fig. 3A) . Recovery of cerebromicrovascular endothelial function with resveratrol was anticipated based on its documented benefit in restoring endothelial function in large vessels of aged mice (31) and in mice with accelerated vascular aging (1, 57) .
The mechanism by which aging impairs cerebromicrovascular endothelial function involves an increased breakdown of NO by elevated levels of ROS. Several lines of evidence support this concept. First, aging is associated with increased ROS production in microvessels both in the brain and other vascular beds (9, 28) . Previous studies suggest that increased activity/expression of NADPH oxidases contribute significantly to aging-induced microvascular oxidative stress (28) . Accordingly, our findings that acute inhibition of NADPH oxidases is able to rescue neurovascular coupling in aged mice (Fig. 4A) provides direct evidence for the role of increased production of NADPH oxidase-derived ROS in cerebromicrovascular endothelial dysfunction (Fig. 1) , extending earlier findings of the laboratory of Iadecola et al. (28) . Interestingly, in A␤-overproducing APP mice CBF is compromised at least in part by enhanced generation of NADPH-derived ROS (29, 30) . Second, we demonstrate that NADPH oxidase expression is significantly upregulated in the brain of aged mice (Fig. 6) . Third, in the microcirculation of aged rodents endotheliumderived NO was shown to react with O 2 Ϫ forming ONOO Ϫ , thus decreasing the bioavailability of NO (9, 27) . Aged mouse brains exhibit an increased 3-nitrotyrosine content (Fig. 4B) , a biomarker of increased ONOO Ϫ formation, suggesting that impaired endothelial mediation of cerebromicrovascular dilation in aging is due to increased scavenging of vasodilator NO (28) .
We propose that resveratrol treatment restores neurovascular coupling and endothelium-dependent cerebromicrovascular dilation in aged mice by attenuating oxidative stress. In support of this concept we demonstrate that resveratrol treatment effectively attenuates age-related cerebral oxidative/nitrative stress, as indicated by the significant decrease in nitrotyrosine content in the brain of aged mice (Fig. 4, B and C) . Further, administration of resveratrol significantly attenuates ROS production in aged CMVECs (Fig. 5, A and B) . Astrocytes are important conduits between neuronal and vascular activity. Important for the present discussion is that aging is also associated with activation of astrocytes (36) and increased ROS production in activated astrocytes (37) may also negatively impact the efficiency of neurovascular coupling. In that regard, it is significant that resveratrol treatment also inhibits ROS production in activated astrocytes in vitro (Fig. 5C ). One can hypothesize that resveratrol treatment of aged mice in addition to its beneficial endothelial effects may also attenuate astrocyte-derived ROS generation, improving neurovascular coupling (e.g., by decreasing production of constrictor arachidonic acid metabolites).
The mechanisms by which resveratrol attenuates NADPH oxidase-derived ROS production are likely multifaceted. We demonstrate that resveratrol treatment results in a significant downregulation of NADPH oxidases in the aged mouse brain (Fig. 6 ). This finding was further confirmed by a parallel in vitro analysis of the effect of resveratrol in aged CMVECs (Fig. 7) . Previously, we showed that resveratrol also downregulates NADPH oxidase in the aorta of aged mice as well (31) . There are also studies showing resveratrol-induced downregulation of NADPH oxidases in the vasculature in pathological conditions associated with accelerated vascular aging (57) . Interestingly, NOX4-containing NADPH oxidase is present in the mitochondria and likely contributes to age-related increases in mitochondrial oxidative stress (11) . In that regard it is important that resveratrol was shown to effectively reduce mitochondrial oxidative stress (47) . In addition, resveratrol may also directly inhibit NADPH oxidase activation via a SIRT1-dependent pathway (54) . Finally, there is also strong evidence that resveratrol activates the transcription factor Nrf2 in the vascular wall, upregulating endogenous antioxidant systems, which likely act in concert to decrease cellular ROS levels produced by NADPH oxidases (46) .
In conclusion, our results demonstrate that resveratrol exerts beneficial cerebromicrovascular effects in aged mice. Resveratrol rescued neurovascular coupling responses to increased neuronal activity in the aged cortex, which likely contributes to improvement of higher cortical function. Our findings, taken together with the results of earlier studies (26) , point to benefits at several levels of cerebrovascular pathology of aging and to the potential use of resveratrol as therapy for prevention of aging-induced cognitive decline (19) . Importantly, neurovascular coupling is compromised both in patients with Alzheimer's disease (AD) ( 15, 21, 22, 24, 34, 35 ) and in experimental models of AD (42) , which is believed to accelerate clinical deterioration. Thus our findings are also likely relevant to the treatment of AD in elderly patients as well.
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